To be or not to be (inflamed)--is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?
about
Oxidative stress-induced signaling pathways implicated in the pathogenesis of Parkinson's diseaseNeuroprotection by spice-derived nutraceuticals: you are what you eat!Uncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repairWnt your brain be inflamed? Yes, it Wnt!Abrogated inflammatory response promotes neurogenesis in a murine model of Japanese encephalitisNeuroprotective activities of palmitoylethanolamide in an animal model of Parkinson's diseaseSalvianolic acid B attenuates toxin-induced neuronal damage via Nrf2-dependent glial cells-mediated protective activity in Parkinson's disease modelsA Wnt1 regulated Frizzled-1/β-Catenin signaling pathway as a candidate regulatory circuit controlling mesencephalic dopaminergic neuron-astrocyte crosstalk: Therapeutical relevance for neuron survival and neuroprotectionMicroglial involvement in neuroplastic changes following focal brain ischemia in rats.Pharmacological properties of BN82451: a novel multitargeting neuroprotective agent.Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic interventionTargeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease.Selective estrogen receptor modulators regulate reactive microglia after penetrating brain injury.Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease.The concept of depression as a dysfunction of the immune systemTFP5, a Peptide Inhibitor of Aberrant and Hyperactive Cdk5/p25, Attenuates Pathological Phenotypes and Restores Synaptic Function in CK-p25Tg Mice.Neurodegeneration and neuroinflammation in cdk5/p25-inducible mice: a model for hippocampal sclerosis and neocortical degeneration.Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases.Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.Differential effects of self-reported lifetime marijuana use on interleukin-1 alpha and tumor necrosis factor in African American adults.Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons.Temporal mRNA profiles of inflammatory mediators in the murine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrimidine model of Parkinson's diseaseFirst joint Italian-German purine club meeting "Progress in Purinergic Receptor Pharmacology and Function".Roles of P2 receptors in glial cells: focus on astrocytesBlockade of adenosine A2A receptors prevents interleukin-1β-induced exacerbation of neuronal toxicity through a p38 mitogen-activated protein kinase pathway.Transplantation of Human Neural Stem Cells in a Parkinsonian Model Exerts Neuroprotection via Regulation of the Host MicroenvironmentPlasticity of subventricular zone neuroprogenitors in MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse model of Parkinson's disease involves cross talk between inflammatory and Wnt/β-catenin signaling pathways: functional consequences for nReactive astrocytes and Wnt/β-catenin signaling link nigrostriatal injury to repair in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.Aging-induced Nrf2-ARE pathway disruption in the subventricular zone drives neurogenic impairment in parkinsonian mice via PI3K-Wnt/β-catenin dysregulation.Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression.Neurodegeneration and cell replacement.Death in the substantia nigra: a motor tragedy.The Anti-Inflammatory Activity of Eucommia ulmoides Oliv. Bark. Involves NF-κB Suppression and Nrf2-Dependent HO-1 Induction in BV-2 Microglial Cells.Clozapine metabolites protect dopaminergic neurons through inhibition of microglial NADPH oxidase.Neuroinflammatory mechanisms in Parkinson's disease: potential environmental triggers, pathways, and targets for early therapeutic interventionAnnexin A1 translocates to nucleus and promotes the expression of pro-inflammatory cytokines in a PKC-dependent manner after OGD/R.Changes of the GPR17 receptor, a new target for neurorepair, in neurons and glial cells in patients with traumatic brain injury.Exacerbated glial response in the aged mouse hippocampus following controlled cortical impact injury.Sesamin modulates tyrosine hydroxylase, superoxide dismutase, catalase, inducible NO synthase and interleukin-6 expression in dopaminergic cells under MPP+-induced oxidative stressMechanisms of over-activated innate immune system regulation in autoimmune and neurodegenerative disorders.
P2860
Q24337079-BD7A16A1-DF12-48A8-8552-FE50A4F479B3Q24635358-FECEFB53-5CC2-4175-8104-84C33200E9B3Q26865502-6B52D669-0815-4103-A3FA-E629F32BA2ACQ27022507-4A38E948-B9D9-47BA-BCAF-E5D447305D67Q27350488-41C7C644-A30E-4E88-B0BF-DF5B2EE1F5F9Q28482356-85115402-0D73-4A65-B0EA-AEB09A1F4B0EQ28540349-343B6E1F-CC46-452E-B345-D7382CCD0DE4Q28589470-D191F708-E7AC-4151-B351-92FB99FCE4C2Q30940972-5D045893-B8DF-4830-955D-4DA5C43996CBQ31130991-CE701BD2-6364-4F10-8C3C-69D4C091CE35Q33663970-E56C7276-6E71-4132-A7CE-CB14A2F34326Q33771694-54BA6C64-FD20-4397-A3C4-177AF654C024Q33782696-2F825486-16CD-4459-9779-D19306DA3672Q34351068-8C9B5196-37C6-4EF8-B491-2876AF66F61AQ34407371-8A7D0307-C22E-4318-BF52-9860DA221402Q34549221-B76ECA28-278C-4E50-8942-A2477664456DQ34737339-5F9DEC29-4128-4AF6-9A31-56AC9B783628Q34784469-CA615A8C-B859-4C44-8A94-D4483807CAEEQ35489240-B8ACE467-4F12-4A6C-A40B-C73FB70369B0Q35587290-A506F35F-2493-4136-8992-349026849C34Q35687315-E537955F-3CDD-472F-8712-C52EF991DEBDQ35846770-2A720DAC-6897-4793-9FBC-2388B5213E92Q36173791-2BA76F5B-F195-4152-A333-D0E49F9D54AAQ36174059-4D3FB0E1-0375-452F-960A-291C27E55B20Q36226674-55A01D02-CCD3-4425-B587-D6CB7F4BA5E8Q36324531-CCAC11C3-B6DB-446C-94B9-0385F1C67C4AQ36566007-09698DF8-6348-4B8C-A9A7-774739C89311Q36573418-F1D862CF-5E3D-49AA-9568-AEC33F020521Q36587894-8F8A912E-B912-4FF5-9ED2-86CDEB7D4DA0Q36692860-A068465D-62AB-4454-A7E5-BE5D54FB1469Q36748869-C4149670-E1C4-495F-9AC0-3F2007403BB5Q36847262-D2295554-DDB7-4F22-9C41-D05D2823CF45Q36879184-B855AF46-93AB-4207-AE5A-8B6B28A4C014Q36907446-8B106814-DA88-485D-8B76-2775A30631C6Q36919403-4A7E1452-08D2-45F8-B2FB-9917978361B2Q37101343-65570F25-DD10-4856-9FD8-CA5A2B58487FQ37131972-25224DA2-00C9-4010-B28C-6964ADA3E02AQ37143217-D0A50716-52B7-46D8-B19C-C97A592E0E8DQ37273506-84311A02-E8F0-419B-8BA9-31223ABA821BQ37418946-5AD0B28F-C1E8-49B0-8635-32713A73992D
P2860
To be or not to be (inflamed)--is that the question in anti-inflammatory drug therapy of neurodegenerative disorders?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
To be or not to be (inflamed)- ...... f neurodegenerative disorders?
@ast
To be or not to be (inflamed)- ...... f neurodegenerative disorders?
@en
type
label
To be or not to be (inflamed)- ...... f neurodegenerative disorders?
@ast
To be or not to be (inflamed)- ...... f neurodegenerative disorders?
@en
prefLabel
To be or not to be (inflamed)- ...... f neurodegenerative disorders?
@ast
To be or not to be (inflamed)- ...... f neurodegenerative disorders?
@en
P1476
To be or not to be (inflamed)- ...... f neurodegenerative disorders?
@en
P304
P356
10.1016/J.TIPS.2005.08.007
P577
2005-10-01T00:00:00Z